1789 TT

ScinoPharm

August 11, 2021

ScinoPharm

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. ("ScinoPharm").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm's **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Table of Content

- Business Overview
- Business Update
- Financial Performance

Business Overview

Stable USD Sales Growth amid Covid-19

- **Supply chain change caused by on-going covid-19 pandemic**
  - **Global logistic striving for recovery**
  - **Customer inventory adjustment**
- **Taiwan level 3 covid-19 alert in 2Q**
  - **Dynamic production and sales planning to adapt the challenge**
- **2021 1H revenue in USD increased 2.1%, yoy**
  - **Due to strong NTD, consolidated revenue was NTD 1,389 million, down 4.3% yoy, with NPAT NTD 181 million, down 8.1% yoy, and NPAT margin 13.0%**

Strengthen Generic API Business
Expand China & Japan Market

- Leverage Tainan/Changshu production advantage with better sales/production coordination to stably supply Japan & China markets
- CFDI's on-site inspection on Changshu site
  - Inspection for Donafenib and Bimatoprost completed in 2021 1H
  - 1 on-site inspections scheduled in 2021 2H
  - 2 customers launched the products after CFDI approval
- 2 CDMO customers obtained approval for Donafenib and Camcevi in China & USA – shipment accommodating launch time; Eflornithine submitted to FDA and EMA by CDMO customer

Changshu Milestone for Upside

- Collaborate with customers to complete CFDI's on-site inspection for their approvals of product launch in China market
- Operations on track for upside

Develop Injectables for future growth

- Profit-sharing from drug products (in-house development + outsourcing production), and various drug products development in progress
- Following the 1st in-house prefilled-syringe product, an in-house liquid solution product was submitted to FDA for ANDA
- Completed the 1st TFDA on-site inspection in April, 2021

Business Update

ScinoPharm

Optimize Generic API Portfolio

Generic API Business Update

- Leverage Tainan/Changshu production advantage and strengthen sales/production coordination to stabilize supply
- The impact of Covid-19 pandemic

Generic API Portfolio



ScinoPharm

Optimize Generic API Portfolio

■ 2021 Generic API Product Approval Plan

Type	Product	Region	Indication	Brand Marketer
Generic API	Fondaparinux Sodium	CN(✓)	Anti-thrombotic	Mylan
Generic API	Irinotecan HCl	CN	Colorectal cancer	Pfizer
Generic API	Anastrozole	CN	Breast cancer	ANI Pharmaceuticals
Generic API	Sodium Phenylbutyrate	CN(✓)	Urea cycle disorders	Horizon Therapeutics
Generic API	Azilsartan	CN	Hypertension	Arbor Pharmaceuticals
Generic API	Letrozole	CN	Breast cancer	Novartis
Generic API	Bimatoprost	CN	Glaucoma	Allergan
Generic API	Regadenoaon	US	MPI	Astellas
Generic API	＊Pemetrexed Disodium $7H_2O$ CEP	EU	Non-small cell lung cancer	Eli Lilly
Generic API	Topiramate	EU	Weight management	Vivus

✓：Approved ＊：Collaborative project for drug product development Data as of 2021/06/30

Expand CDMO Business

CDMO Business



Data as of 2021/06/30

ScinoPharm

Expand CDMO Business

2021 CDMO API Product Approval Plan

Type	Product	Region	Indication	Brand Marketer
CDMO API	Donafenib	CN(✓)	Cancer	Suzhou Zelgen
CDMO API	Camcevi	US(✓) EU	Cancer	Foresee
CDMO API	Eflornithine	US/EU	FAP	CPP

Data as of 2021/06/30

- Donafenib (NCE) was approved and launched in China in June, 2021
- Camcevi (NCE) was approved by FDA in June, 2021; MAA review in progress
- Eflornithine submitted to FDA and EMA by customer

Advancing to Injectables



Peptides

Sterile Injectables

Pen Injectors

- Profit-sharing from 3 drug products (in-house development + outsourcing production)
- ANDA of 1st in-house prefilled-syringe product was submitted to FDA in May, 2020 - Response to FDA in progress
- ANDA of 1st in-house liquid solution product was submitted to FDA in June, 2021
- Registration batches of Vial line (prefilled-syringed /pen device) and Cartridge line (liquid solution/ lyophilized powder) products were completed
- Completed the 1st TFDA on-site inspection in April, 2021, official inspection report received in June and replied in July, TFDA's review in progress

Actively Develop Japan, China and Emerging Markets

Japan Market

- The impact of Covid-19 pandemic
- The largest generic API supplier for Galantamine HBr and Capecitabine in Japan
  - Indication：Alzheimer's disease / Various cancers
  - Japan market size：c. USD 200 million / over USD 100 million
- Leverage Japan's late patent expiration and our new injectables capacity to explore opportunities for generic APIs + CDMO projects

Actively Develop Japan, China and Emerging Markets

China Market

- Customer's Fondaparinux Sodium PFS launched in Feb. 2021
  - Indication：Anti-thrombotic
  - Market Size：c. RMB 200 million
- CFDI on-site inspection in Changshu site

Inspection	Product	Approval	Indication	Market
2020.09	Sodium Phenylbutyrate	2021.05	Urea cycle disorders	Urea cycle disorders
2021.02	Donafenib	2021.06	Advanced liver cancer first-line treatment	1st year sales projected by research report：c. RMB 220 million
2021.06	Bimatoprost	Expect in year-end of 2021	Glaucoma	c. RMB 1 billion

- Changshu site expects to activate one more inspections in 2021

Financial Performance

Consolidated Income Statement

In NTD Million, except for EPS	1H 2021 (Reviewed)		YoY	1H 2020 (Reviewed)	
Revenue	1,389	100%	-4%	1,451	100%
Gross Profit	702	51%	3%	682	47%
Operating Profit	221	16%	-12%	252	17%
Net Profit before Tax	224	16%	-11%	252	17%
Net Profit after Tax	181	13%	-8%	197	14%
EPS (NTD)	0.23	-	-	0.25	-

1H 2021 Sales Distribution



by Business



by Region



by Indication

ScinoPharm

Sales Distribution – YoY

By Business

Unit: USD

	Generic API	CDMO	Drug Product
1H 2021 Sales	41.0M	6.3M	2.0M
YoY	4.9%	-27.6%	276.9%

By Indication

	Oncology	CNS	Others
1H 2021 Sales	33.0M	12.9M	3.4M
YoY	-3.9%	19.2%	9.2%

By Region

	EU	US & Canada	Japan	India	China	Others
1H 2021 Sales	12.1M	12.2M	14.8M	1.9M	3.2M	5.1M
YoY	-30.5%	9.9%	81.3%	-74.4%	253.6%	54.0%

Consolidated Balance Sheet

In NTD Million	2021/6/30 (Reviewed)		2020/6/30 (Reviewed)	
Cash and Cash Equivalents	4,104	34%	3,803	31%
Accounts Receivable	355	3%	554	5%
Inventories	1,449	12%	1,299	11%
Property, Plant & Equipment	4,100	34%	4,255	35%
Other Current/Non-Current Assets	2,070	17%	2,197	18%
Total Assets	**12,078**	**100%**	**12,108**	**100%**
Financial Debt	40	0%	261	2%
Other Current Liabilities	1,027	9%	830	7%
Other Non-Current Liabilities	626	5%	636	5%
Total Liabilities	**1,693**	**14%**	**1,727**	**14%**
Total Shareholders' Equities	**10,385**	**86%**	**10,381**	**86%**

Consolidated Cash Flow Statement

In NTD million	1H 2021 (Reviewed)	1H 2020 (Reviewed)
From Operating Activities	180	368
From Investing Activities	(152)	123
From Financing Activities	27	29
Effect of foreign exchange rate changes	(6)	(22)
Net Change in Cash	49	498
Beginning Balance	4,055	3,305
Ending Balance	4,104	3,803

Q & A

Appendix

Company Overview

ScinoPharm at a Glance

- Est. in 1997 in Taiwan (Tainan) with cGMP plants/R&D in Tainan and Changshu and marketing forces in Tainan, Shanghai and Tokyo
- Specializes in high potency (cytotoxic/steroid) API and injectable R&D and manufacturing with customers worldwide
- 74 generic APIs in portfolio with 32 referred and approved by ANDA/NDA*
  - 874 active DMFs worldwide with 64 US DMFs*
- 150+ contract projects with 8 approved/launched (6 NCEs) and 7 in phase 3 for NDA/MAA filing in 1-3 years*
- Certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority

* Data as of 2021/06/30



Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT